INOZYME PHARMA INC (INZY) Stock Balance Sheet
NASDAQ:INZY - Nasdaq - US45790W1080 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 21.08M | 34.59M | 32.90M | 23.30M | 28.00M | |||
| Marketable Securities | 92.01M | 154.00M | 95.00M | 88.50M | 119.70M | |||
| Receivables | 467.00K | 385.00K | 100.00K | 100.00K | 200.00K | |||
| Other Current Assets | 7.12M | 7.28M | 3.40M | 3.50M | 3.10M | |||
| Total Current Assets | 120.68M | 196.25M | 131.40M | 115.30M | 151.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.35M | 2.59M | 3.60M | 4.40M | 2.60M | |||
| Investments And Advances | N/A | N/A | N/A | 0.00 | 12.20M | |||
| Other Non-Current Assets | 1.16M | 2.00M | 4.20M | 3.80M | 3.50M | |||
| Total Non-Current Assets | 2.51M | 4.60M | 7.80M | 8.20M | 18.40M | |||
| TOTAL ASSETS | 123.18M | 200.85M | 139.20M | 123.50M | 169.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 14.50M | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 16.87M | 13.52M | 12.20M | 9.20M | 6.60M | |||
| Accounts Payable | 2.53M | 1.17M | 2.50M | 2.40M | 3.10M | |||
| Other Current Liabilities | N/A | N/A | N/A | 0.00 | 300.00K | |||
| Total Current Liabilities | 33.90M | 14.69M | 14.70M | 11.60M | 10.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 31.46M | 44.77M | 4.10M | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 0.00 | 913.00K | 1.90M | 2.60M | 1.30M | |||
| Total Non-Current Liabilities | 31.46M | 45.68M | 6.10M | 2.70M | 1.30M | |||
| TOTAL LIABILITIES | 65.36M | 60.37M | 20.80M | 14.30M | 11.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -387.95M | -285.93M | -214.80M | -147.70M | -91.10M | |||
| Additional Paid In Capital | 445.70M | 426.36M | 333.40M | 256.90M | 249.20M | |||
| Common Shares | 6.00K | 6.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 69.00K | 41.00K | -200.00K | 0.00 | 0.00 | |||
| Shares Outstanding | 64.24M | 61.77M | 40.40M | 23.70M | 23.40M | |||
| Tangible Book Value per Share | 0.90 | 2.27 | 2.93 | 4.61 | 6.76 | |||
| Total Shareholders' Equity | 57.83M | 140.48M | 118.40M | 109.30M | 158.10M | |||
| TOTAL LIABILITIES AND EQUITY | 123.18M | 200.85M | 139.20M | 123.50M | 169.40M | |||
| Statistics | ||||||||
| Debt/Equity | 0.54 | 0.32 | 0.03 | N/A | N/A | |||
| Current Ratio | 3.56 | 13.36 | 8.94 | 9.94 | 15.10 | |||
| Return On Assets (ROA) | -82.82% | -35.43% | -48.18% | -45.85% | -33.31% | |||
| Return On Equity (ROE) | -176.43% | -50.66% | -56.64% | -51.80% | -35.69% | |||
All data in USD , ROIC based on taxRate of 0.21